Adaptive Biotechnologies (ADPT) Income from Continuing Operations: 2017-2024
Historic Income from Continuing Operations for Adaptive Biotechnologies (ADPT) over the last 8 years, with Dec 2024 value amounting to -$159.6 million.
- Adaptive Biotechnologies' Income from Continuing Operations rose 129.74% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$79.6 million, marking a year-over-year increase of 59.25%. This contributed to the annual value of -$159.6 million for FY2024, which is 29.16% up from last year.
- Per Adaptive Biotechnologies' latest filing, its Income from Continuing Operations stood at -$159.6 million for FY2024, which was up 29.16% from -$225.3 million recorded in FY2023.
- In the past 5 years, Adaptive Biotechnologies' Income from Continuing Operations ranged from a high of -$146.2 million in FY2020 and a low of -$225.3 million during FY2023.
- Over the past 3 years, Adaptive Biotechnologies' median Income from Continuing Operations value was -$200.4 million (recorded in 2022), while the average stood at -$195.1 million.
- In the last 5 years, Adaptive Biotechnologies' Income from Continuing Operations plummeted by 113.14% in 2020 and then increased by 29.16% in 2024.
- Yearly analysis of 5 years shows Adaptive Biotechnologies' Income from Continuing Operations stood at -$146.2 million in 2020, then tumbled by 41.76% to -$207.3 million in 2021, then grew by 3.34% to -$200.4 million in 2022, then dropped by 12.45% to -$225.3 million in 2023, then grew by 29.16% to -$159.6 million in 2024.